CNB-001 a novel curcumin derivative, guards dopamine neurons in MPTP model of Parkinson's disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Jayaraj, Richard L ^a   Elangovan, Namasivayam ^a   Manigandan, Krishnan ^a   Singh, Sonu ^b   Shukla, Shubha ^b  

^a PERIYAR UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4,4' [(1 PHENYL 1H PYRAZOLE 3,5 DIYL)DIETHENE 2,1 DIYL]BIS(2 METHOXYPHENOL); CATALASE; DOPAMINE TRANSPORTER; GLUTATHIONE; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; CURCUMIN; NEUROPROTECTIVE AGENT; PYRAZOLE DERIVATIVE;

ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN MITOCHONDRION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; REDUCTION; SUBSTANTIA NIGRA; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; DRUG EFFECTS; HUMAN; METABOLISM; MPTP POISONING; PATHOLOGY;

ANIMALS; BRAIN; CURCUMIN; DOPAMINERGIC NEURONS; GLUTATHIONE PEROXIDASE; HUMANS; MICE; MPTP POISONING; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PYRAZOLES;

EID: 84904101366     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/236182     Document Type: Article

References (45)

1. Jankovic J., Parkinson's disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry 2008 79 4 368 376 2-s2.0-41149163183 10.1136/jnnp.2007.131045 (Pubitemid 351441488)
2. Dauer W., Przedborski S., Parkinson's disease: mechanisms and models. Neuron 2003 39 6 889 909 2-s2.0-0141741347 10.1016/S0896-6273(03)00568-3 (Pubitemid 37130207)
3. Spina M. B., Cohen G., Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America 1989 86 4 1398 1400 2-s2.0-0345724066 (Pubitemid 19061553)
4. Heikkila R. E., Sonsalla P. K., The MTPT-treated mouse as a model of Parkinsonism: how good is it? Neurochemistry International 1992 20 supplement 1 299S 303S 2-s2.0-0026552602
5. Miller G. W., Erickson J. D., Perez J. T., Penland S. N., Mash D. C., Rye D. B., Levey A. I., Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Experimental Neurology 1999 156 1 138 148 2-s2.0-0033030440 10.1006/exnr.1998.7008 (Pubitemid 29152991)
6. Schapira A. H., Mitochondria in the aetiology and pathogenesis of Parkinson's disease. The Lancet Neurology 2008 7 1 97 109 2-s2.0-37049004489 10.1016/S1474-4422(07)70327-7 (Pubitemid 350251942)
7. Li N., Ragheb K., Lawler G., Sturgis J., Rajwa B., Melendez J. A., Robinson J. P., Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. The Journal of Biological Chemistry 2003 278 10 8516 8525 2-s2.0-0037424245 10.1074/jbc.M210432200 (Pubitemid 36800604)
8. + uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. British Journal of Pharmacology 1993 109 2 411 414 2-s2.0-0027160147 (Pubitemid 23161124)
9. Tintner R., Jankovic J., Treatment options for Parkinson's disease. Current Opinion in Neurology 2002 15 4 467 476 2-s2.0-0036315556 10.1097/00019052-200208000-00011 (Pubitemid 34828125)
10. Cole G. M., Teter B., Frautschy S. A., Neuroprotective effects of curcumin. Advances in Experimental Medicine and Biology 2007 595 197 212 2-s2.0-34347216379 10.1007/978-0-387-46401-5-8
11. Liu Y., Dargusch R., Maher P., Schubert D., A broadly neuroprotective derivative of curcumin. Journal of Neurochemistry 2008 105 4 1336 1345 2-s2.0-42549169394 10.1111/j.1471-4159.2008.05236.x (Pubitemid 351590797)
12. Valera E., Dargusch R., Maher P. A., Schubert D., Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease. Journal of Neuroscience 2013 33 25 10512 10525 2-s2.0-84879128268 10.1523/JNEUROSCI.5183- 12.2013
13. Jayaraj R. L., Tamilselvam K., Manivasagam T., Elangovan N., Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease. Journal of Molecular Neuroscience 2013 51 3 863 870 2-s2.0-84880691646 10.1007/s12031-013-0075-8
14. Antzoulatos E., Jakowec M. W., Petzinger G. M., Wood R. I., Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease. Pharmacology Biochemistry and Behavior 2010 95 4 466 472 2-s2.0-77952547832 10.1016/j.pbb.2010.03.009
15. Lau Y.-S., Novikova L., Roels C., MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. Neuroscience Research 2005 52 4 371 378 2-s2.0-21444451858 10.1016/j.neures.2005.04.010
16. Narumoto O., Matsuo Y., Sakaguchi M., Shoji S., Yamashita N., Schubert D., Abe K., Horiguchi K., Nagase T., Yamashita N., Suppressive effects of a pyrazole derivative of curcumin on airway inflammation and remodeling. Experimental and Molecular Pathology 2012 93 1 18 25 2-s2.0-84860787059 10.1016/j.yexmp.2012.04.011
17. Rozas G., López-Martín E., Guerra M. J., Labandeira-García J. L., The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. Journal of Neuroscience Methods 1998 83 2 165 175 2-s2.0-0032168609 10.1016/S0165-0270(98)00078-8 (Pubitemid 28442608)
18. Tillerson J. L., Miller G. W., Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. Journal of Neuroscience Methods 2003 123 2 189 200 2-s2.0-0037445497 10.1016/S0165-0270(02)00360-6 (Pubitemid 36279413)
19. RajaSankar S., Manivasagam T., Surendran S., Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease. Neuroscience Letters 2009 454 1 11 15 2-s2.0-62349087989 10.1016/j.neulet.2009.02.044
20. Franklin K. B. J., Paxinos G., The Mouse Brain in Stereotaxic Coordinates 2007 London, UK Academic Press
21. Bhattacharya A., Ghosal S., Bhattacharya S. K., Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. Journal of Ethnopharmacology 2001 74 1 1 6 2-s2.0-0035200453 10.1016/S0378-8741(00)00309-3 (Pubitemid 32008512)
22. Jollow D. J., Mitchell J. R., Zampaglione N., Gillette J. R., Bromobenzene induced liver necrosis. Protective role of glutathione and evidence for 3,4 bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 1974 11 3 151 169 2-s2.0-0016151122
23. Yamamoto Y., Takahashi K., Glutathione peroxidase isolated from plasma reduces phospholipid hydroperoxides. Archives of Biochemistry and Biophysics 1993 305 2 541 545 2-s2.0-0027246660 10.1006/abbi.1993.1458 (Pubitemid 23282943)
24. Oberley L. W., Spitz D. R., Assay of superoxide dismutase activity in tumor tissue. Methods in Enzymology 1984 105 457 464 2-s2.0-0021288861 (Pubitemid 14165412)
25. Aebi H., Catalase in vitro. Methods in Enzymology 1984 105 121 126 2-s2.0-0021318441 10.1016/S0076-6879(84)05016-3
26. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry 1951 193 1 265 275 2-s2.0-71849104860
27. Brown G. C., Borutaite V., Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochimica et Biophysica Acta: Bioenergetics 2004 1658 1-2 44 49 2-s2.0-3543008400 10.1016/j.bbabio.2004.03.016 (Pubitemid 39013232)
28. Jayaraj R. L., Elangovan N., In vitro antioxidant potential and DNA protecting activity of CNB-001, a novel pyrazole derivative of curcumin. Chronicles of Young Scientists 2014 5 44 52 10.4103/2229-5186.129338
29. Hanakawa T., Katsumi Y., Fukuyama H., Honda M., Hayashi T., Kimura J., Shibasaki H., Mechanisms underlying gait disturbance in Parkinson's disease. A single photon emission computed tomography study. Brain 1999 122 7 1271 1282 2-s2.0-0032767876 10.1093/brain/122.7.1271 (Pubitemid 29324848)
30. Crocker S. J., Liston P., Anisman H., Lee C. J., Smith P. D., Earl N., Thompson C. S., Park D. S., Korneluk R. G., Robertson G. S., Attenuation of MPTP-induced neurotoxicity and behavioural impairment in NSE-XIAP transgenic mice. Neurobiology of Disease 2003 12 2 150 161 2-s2.0-0345268775 10.1016/S0969-9961(02)00020-7 (Pubitemid 36349406)
31. Fredriksson A., Archer T., MPTP-induced behavioural and biochemical deficits: a parametric analysis. Journal of Neural Transmission: Parkinson's Disease and Dementia Section 1994 7 2 123 132 2-s2.0-0028174377 10.1007/BF02260967 (Pubitemid 24158184)
32. Thiffault C., Aumont N., Quirion R., Poirier J., Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. Journal of Neurochemistry 1995 65 6 2725 2733 2-s2.0-0028971624 (Pubitemid 3002930)
33. Toffa S., Kunikowska G. M., Zeng B.-Y., Jenner P., Marsden C. D., Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. Journal of Neural Transmission 1997 104 1 67 75 2-s2.0-0031025924 10.1007/BF01271295 (Pubitemid 27073230)
34. Fon E. A., Pothos E. N., Sun B.-C., Killeen N., Sulzer D., Edwards R. H., Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 1997 19 6 1271 1283 2-s2.0-0031458637 10.1016/S0896-6273(00)80418-3 (Pubitemid 28030546)
35. Anandhan A., Janakiraman U., Manivasagam T., Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease. Neuroscience 2012 218 257 267 2-s2.0-84863779700 10.1016/j.neuroscience.2012.05.039
36. Rekha K. R., Selvakumar G. P., Sethupathy S., Santha K., Sivakamasundari R. I., Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson's disease. Journal of Molecular Neuroscience 2013 51 3 851 862 2-s2.0-84881280054 10.1007/s12031-013- 0074-9
37. Wang Y.-M., Gainetdinov R. R., Fumagalli F., Xu F., Jones S. R., Bock C. B., Miller G. W., Wightman R. M., Caron M. G., Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 1997 19 6 1285 1296 2-s2.0-0031458923 10.1016/S0896-6273(00)80419-5 (Pubitemid 28030547)
38. Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A. C., Mazzulli J., Mosharov E. V., Hodara R., Fredenburg R., Wu D.-C., Follenzi A., Dauer W., Przedborski S., Ischiropoulos H., Lansbury P. T., Sulzer D., Cuervo A. M., Dopamine-modified α -synuclein blocks chaperone-mediated autophagy. Journal of Clinical Investigation 2008 118 2 777 778 2-s2.0-38849174979 10.1172/JCI32806 (Pubitemid 351206565)
39. Mosharov E. V., Larsen K. E., Kanter E., Phillips K. A., Wilson K., Schmitz Y., Krantz D. E., Kobayashi K., Edwards R. H., Sulzer D., Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009 62 2 218 229 2-s2.0-65249180086 10.1016/j.neuron.2009.01.033
40. Wilson J. M., Kalasinsky K. S., Levey A. I., Bergeron C., Reiber G., Anthony R. M., Schmunk G. A., Shannak K., Haycock J. W., Kish S. J., Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Medicine 1996 2 6 699 703 2-s2.0-15844384993 10.1038/nm0696-699 (Pubitemid 26191961)
41. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y., Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease. Biochemical and Biophysical Research Communications 1989 163 3 1450 1455 2-s2.0-0024330311 (Pubitemid 19244751)
42. Parker W. D. Jr., Boyson S. J., Parks J. K., Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Annals of Neurology 1989 26 6 719 723 2-s2.0-0024848034 10.1002/ana.410260606 (Pubitemid 20011004)
43. Trimmer P. A., Swerdlow R. H., Parks J. K., Keeney P., Bennett J. P. Jr., Miller S. W., Davis R. E., Parker W. D. Jr., Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Experimental Neurology 2000 162 1 37 50 2-s2.0-0034102780 10.1006/exnr.2000.7333 (Pubitemid 30170099)
44. Anglade P., Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histology and Histopathology 1997 12 3 603 610 2-s2.0-0030738721 (Pubitemid 27314689)
45. Binukumar B. K., Bal A., Kandimalla R. J. L., Gill K. D., Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, α synuclein aggregation, oxidative damage and behavioral changes. Molecular Brain 2010 3 1, article 35 2-s2.0-78649903669 10.1186/1756-6606-3-35